Eli Lillys triple agonist, retatrutide, demonstrated an average weight loss of 16.8% in a Phase 3 trial for the treatment of type 2 diabetes, the company announced today
J Neuroinflamm (2018) 15:337
and it may increase the risk of hypoglycaemia when used with insulin or sulfonylureas
6 In a randomized, controlled, crossover study in healthy subjects, consuming 180 mg of curcumin before a carbohydrate-rich meal significantly reduced the incremental area under the curve for plasma glucose over 120 minutes by approximately 36 percent compared with control, without major adverse events
Liu J, Wang F, Liu S, Du J, Hu X, Xiong J, et al